Michael Martin has left his president and chief executive roles at Takeda Ventures, the US corporate venturing arm of Japanese pharmaceutical firm Takeda, and joined protein degradation therapy developer Plexium.
Martin joined the parent firm in 2012 when Intellikine, the cancer treatment company he worked for at the time, was acquired by Takeda at the end of 2011. He joined Takeda Ventures in 2015 and was named the unit’s global head two years later. GCV included him on the 2022 Powerlist.
At Plexium, Martin has taken up similar roles to help the company further develop its drugs for areas including oncology, dermatology, immunology, neuroscience and respiratory diseases.
“With our lead programme PLX-4545 in phase 1 and an emerging pipeline of transformative therapeutics, I believe that the future is bright at Plexium,” Martin said on LinkedIn.
Plexium is backed by investors including corporates SoftBank’s Vision Fund 2, Merck Group’s M Ventures and Pivotal BioVenture Partners, part of Nan Fung Life Sciences.
